Search results
Showing 1651 to 1665 of 8905 results
Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.
Burosumab for treating X-linked hypophosphataemia in adults (TA993)
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults.
Awaiting development Reference number: GID-TA10393 Expected publication date: TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]
In development Reference number: GID-TA10497 Expected publication date: TBC
In development Reference number: GID-TA10542 Expected publication date: TBC
Gosuranemab for treating progressive supranuclear palsy [ID1607]
Awaiting development Reference number: GID-TA10553 Expected publication date: TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]
In development Reference number: GID-TA10573 Expected publication date: TBC
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]
Awaiting development Reference number: GID-TA10604 Expected publication date: TBC
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]
Awaiting development Reference number: GID-TA10431 Expected publication date: TBC
Awaiting development Reference number: GID-TA10439 Expected publication date: TBC
In development Reference number: GID-TA10446 Expected publication date: TBC
Awaiting development Reference number: GID-TA10453 Expected publication date: TBC
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]
Awaiting development Reference number: GID-TA10823 Expected publication date: TBC
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]
Awaiting development Reference number: GID-TA10867 Expected publication date: TBC